BioNTech SE (VIE:BNTX)
Austria · Delayed Price · Currency is EUR 80.35
+2.20 (2.82%)
At close: Aug 7, 2026
BioNTech SE Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -1,686 | -1,136 | -665.3 | 930.3 | 9,434 | 10,293 |
Depreciation & Amortization | 676.4 | 382.8 | 298 | 183.4 | 123.3 | 75.2 |
Stock-Based Compensation | 95.7 | 106.2 | 100.9 | 51.4 | 108.6 | 93.9 |
Other Adjustments | 185.4 | 185.7 | -770.2 | -372.2 | 3,659 | 4,641 |
Change in Receivables | 1,760 | 1,084 | 387.7 | 5,374 | 4,370 | -11,808 |
Changes in Inventories | 131.5 | 177.9 | 74.5 | 81.9 | 62.9 | -438.4 |
Changes in Accounts Payable | -814.6 | -723.8 | 758.4 | 118.9 | 85.7 | 1,516 |
Changes in Income Taxes Payable | -26.8 | 3.8 | -389.2 | -482.9 | -4,222 | -3,458 |
Changes in Other Operating Activities | 358.7 | 375.8 | 412.9 | -513.4 | -44 | -24.4 |
Operating Cash Flow | 679.7 | 456 | 207.7 | 5,371 | 13,577 | 889.7 |
Operating Cash Flow Growth | - | 119.55% | -96.13% | -60.44% | 1426.07% | - |
Capital Expenditures | -210.5 | -175.1 | -286.5 | -249.4 | -329.2 | -127.5 |
Sale of Property, Plant & Equipment | 8.5 | 4.5 | 1.2 | -0.7 | 0.6 | 3.4 |
Purchases of Intangible Assets | -24.5 | -573.9 | -165.8 | -455.4 | -34.1 | -26.5 |
Purchases of Investments | -10,851 | -11,423 | -12,370 | -7,128 | -47.8 | -19.5 |
Proceeds from Sale of Investments | 9,712 | 9,512 | 10,740 | 1,216 | 375.2 | -375.2 |
Cash Acquisitions | 264.8 | 186.3 | - | -336.9 | - | -20.8 |
Investing Cash Flow | -1,100 | -2,469 | -2,081 | -6,955 | -35.3 | -566.1 |
Long-Term Debt Issued | - | 6.7 | - | 0.3 | 0.8 | - |
Long-Term Debt Repaid | -15.7 | -18 | -2.3 | -0.1 | -18.8 | -52.6 |
Net Long-Term Debt Issued (Repaid) | -15.7 | -11.3 | -2.3 | 0.2 | -18 | -52.6 |
Issuance of Common Stock | - | - | - | - | 110.5 | 160.9 |
Repurchase of Common Stock | -129.2 | - | - | -738.5 | -986.4 | - |
Net Common Stock Issued (Repurchased) | -129.2 | - | - | -738.5 | -875.9 | 160.9 |
Common Dividends Paid | - | - | - | - | -484.3 | - |
Other Financing Activities | -43.9 | -41.6 | -43.6 | -40.3 | -41.1 | -14.1 |
Financing Cash Flow | -107.9 | -52.9 | -45.9 | -778.6 | -1,419 | 94.2 |
Foreign Exchange Rate Adjustments | -26.8 | -27 | 14.8 | -14.5 | 60.1 | 64.7 |
Net Cash Flow | -330.5 | -2,065 | -1,919 | -2,362 | 12,123 | 417.8 |
Free Cash Flow | 469.2 | 280.9 | -78.8 | 5,122 | 13,248 | 762.2 |
Free Cash Flow Growth | - | - | - | -61.34% | 1638.15% | - |
FCF Margin | 19.34% | 9.20% | -2.73% | 130.53% | 76.53% | 4.02% |
Free Cash Flow Per Share | 1.87 | 1.16 | -0.33 | 21.10 | 53.04 | 2.93 |
Levered Free Cash Flow | -1,587 | -1,106 | 200.5 | 69 | 5,093 | 7,783 |
Unlevered Free Cash Flow | -1,950 | -1,478 | -422.15 | -319.99 | 4,884 | 7,998 |